Interview Questions for Daniel De Carvalho
Daniel De Carvalho responses to interview questions from Tal Behar, Precision World Medicine Conference Daniel D. De Carvalho, PhDProfessor, University of Toronto; ALLAN SLAIGHT Senior Scientist, Princess Margaret Cancer Centre/University Health Network; Co-Founder and CSO, Adela Where does methylation add indispensable value in MRD vs mutation‑only approaches (e.g., low‑shedding tumors, tissue‑of‑origin context, earlier relapse […]
Interview Questions for Serge Saxonov, 10x Genomics
Serge Saxonov’s (10x Genomics) responses to interview questions from Tal Behar, Precision World Medicine Conference Q1. Single-cell and spatial assays are powering translational research but aren’t yet routine diagnostics. What’s the biggest barrier — scientific, regulatory, or cultural — to bringing these technologies into clinical use? The biggest barrier right now is clinical evidence. We […]
Interview Questions for Klaus Pantel
RE: I believe that a combination of these liquid biopsy approaches holds most promise for improving cancer screening and would also include non-ctDNA biomarkers such as circulating extracellular vesicles, proteins, metabolites, RNAs and tumor cells. Such a composite biomarker panel is currently evaluated for early pancreatic cancer screening in the EU Horizon consortium PANCAID (https://pancaid-project.eu; Lead-PI: K. Pantel). Challenges that must b
Interview Questions for Curtis P. Langlotz
Curtis P. Langlotz’s responses to interview questions from Tal Behar, Precision World Medicine Conference Curtis P. Langlotz, Professor of Radiology, Medicine, and Biomedical Data Science Senior Associate Vice Provost for Research Director, Center for Artificial Intelligence in Medicine & Imaging Senior Fellow, Institute for Human-Centered Artificial Intelligence 1. If you could mandate one […]
Interview Questions for Levi Garraway
Levi Garraway’s responses to interview questions from Tal Behar, Precision World Medicine Conference 1. IO focus: If you could green-light one immuno-oncology combination for a definitive Phase 3 in 2026, which patients benefit, and what one biomarker makes or breaks it? In solid tumors, it seems as though we may be entering an era where […]
Interview Questions for Keith Booher
1. Your talk emphasizes AI-driven workflows for identifying repurposed drugs. Can you share a specific case where your platform identified a treatment for a rare disease, and how it impacted patient outcomes?”
Interview Questions for Mike Snyder, PhD, Stanford
1. Can you describe a project or experience where you integrated data from wearables with multi-omics data? What were the main challenges you faced, and how did you address them?
We have several projects running right
Can Proteomics Transform Cancer Prevention? Learn from Dr. Stefánsson at PMWC Feb 5-7 – Healthcare Professional
Can we predict and prevent cancer before it strikes? Dr. Kári Stefánsson, founder of deCODE Genetics, is leading the way.
Breaking: New Quantum Chip cuts Eons to 5min! – Hear from Nvidia’s CEO on AI in Healthcare + FDA Commissioner on AI concerns + more at PMWC Feb 5-7
The future of medicine is here—and it’s powered by AI. Imagine a world where AI personalizes your treatment, transforms how diseases are detected, and revolutionizes drug development. At PMWC 2025, February 5-7 in the Santa Clara Convention Center, we’ll bring this vision to life, showcasing how AI is reshaping healthcare and accelerating precision medicine.
Interview Questions for Dan Chen, MD, PhD, Genesis Biocapital
1. With your extensive background at Genentech and foundational contributions to the Cancer-Immunity Cycle, can you share some insights on the key challenges and breakthroughs in cancer immunotherapy over the past decade, and how these have influenced the development of new therapies?
